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The present study describes the synthesis, characterization, antileishmanial and antiplasmodial activities of novel
diimine/(2,2′-bipyridine (bipy), 1,10-phenanthroline (phen), 4,4′-methylbipyridine (Me-bipy) and 4,4′-
methoxybipyridine (MeO-bipy)/phosphine/ruthenium(II) complexes containing lapachol (Lap, 2-hydroxy-3-
(3-33 methyl-2-buthenyl)-1,4-naphthoquinone) as bidentate ligand. The [Ru(Lap)(PPh3)2(bipy)]PF6 (1),
[Ru(Lap)(PPh3)2(Me-bipy)]PF6 (2), [Ru(Lap)(PPh3)2(MeO-bipy)]PF6 (3) and[Ru(Lap)(PPh3)2(phen)]PF6 (4)
complexes, PPh3 = triphenylphospine, were synthesized from the reactions of cis-[RuCl2(PPh3)2(X-bipy)] or
cis-[RuCl2(PPh3)2(phen)],with lapachol. The [RuCl2(Lap)(dppb)] (5) [dppb=1,4-bis(diphenylphosphine)butane]
was synthesized from the mer-[RuCl3(dppb)(H2O)] complex. The complexes were characterized by elemental
analysis, molar conductivity, infrared and UV–vis spectroscopy, 31P{1H} and 1H NMR, and cyclic voltammetry.
The Ru(III) complex, [RuCl2(Lap)(dppb)], was also characterized by the EPR technique. The structure of the com-
plexes [Ru(Lap)(PPh3)2(bipy)]PF6 and [RuCl2(Lap)(dppb)] was elucidated by X-ray diffraction. The evaluation of
the antiparasitic activities of the complexes against Leishmania amazonensis and Plasmodium falciparum demon-
strated that lapachol–ruthenium complexes aremore potent than the free lapachol. The [RuCl2(Lap)(dppb)] com-
plex is themost potent and selective antiparasitic compound among theﬁve new ruthenium complexes studied in
this work, exhibiting an activity comparable to the reference drugs.
© 2014 Published by Elsevier Inc.
1. Introduction
Leishmaniasis and malaria are diseases caused by protozoan
parasites and are characterized by high morbidity. It is estimated that
leishmania disease causes about seventy thousand deaths annually
and malaria kills around 1 million children only in Africa [1]. The ﬁrst
line treatment for leishmaniasis still relies on the use of pentavalent
antimonials, although other drugs are also used for the treatment of
Leishmania infection, such as pentamidine isethionate, amphotericin B
and miltefosine [2,3]. Malaria treatment relies on the use of quinoline-
based drugs, such as chloroquine, primaquine and meﬂoquine, as well
as antifolates and artemisinin derivatives, depending on the parasite's
susceptibility [4]. Common problems with these antiparasitic drugs
are severe side effects and development of drug resistance. Based on
this scenery, the research of new active compounds against these para-
sites is pivotal.
The Tabebuia genus, belonging to the bignoniaceae plant family, is
widely used in the traditional medicine in South America [5,6]. Among
the active secondary metabolites present in this genus, 2-hydroxy-3-
(3-methyl-2-buthenyl)-1,4-naphthoquinone (lapachol, Fig. 1) is one
of the most studied. Lapachol is endowed with anticancer and antimi-
crobial properties [7,8]. Because of its antiproliferative activity, lapachol
has been employed as a prototype for the design and synthesis of new
anticancer and antimicrobial agents. This has led to the identiﬁcation
of fewer lapachol derivatives with an enhanced activity [9–12].
Like other naphthoquinones [13,14], lapachol is a feasible ligand for
the preparation of coordinating or organometallic compounds. In fact,
there are some ﬁndings showing that lapachol–metal complexes are bi-
ologically more active than the free molecule [15–18]. Ruthenium com-
plexes are considered to be one of the most promising types of metal
compounds for cancer treating, due its interesting chemical properties,
such as: versatility in ligand exchange, octahedral geometry and vari-
ability of oxidation states [19,20]. Recently it was observed that the
lapachol–Ru(II) complex is a more potent anticancer agent than
lapachol–Os(II) and Rh(III) complexes [18], suggesting that the use of
ruthenium is promising to improve the biological activity of lapachol.
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Therefore, the present study describes the synthesis, characterization,
antileishmanial and antiplasmodial activities of novel diimines (2,2′-
bipyridine (bipy), 1,10-phenantroline (phen), 4,4′-methylbipyridine
(Me-bipy) and 4,4′-methoxybipyridine (MeO-bipy) andmonophosphine
ruthenium(II) and (III) complexes containing lapachol as a bidentate
ligand.
2. Experimental section
2.1. Materials for synthesis
Solventswere puriﬁed by standardmethods. All chemicals usedwere
of reagent grade or comparable purity. The RuCl3∙3H2O was purchased
fromDegussa or Aldrich. The ligands 1,4-bis(diphenylphosphino)butane
(dppb), triphenylphosphine (TPP), bipy, Me-bipy, MeO-bipy and phen
were used as received from Aldrich.
2.2. Instrumentation
Elemental analyses were performed in a Fisons EA 1108 model
(Thermo Scientiﬁc). The IR spectra of the powder complexes were re-
corded using CsI pellets in the 4000–200 cm−1 region in a Bomen–
Michelson FT MB-102 instrument. The UV–Visible (UV–vis) spectra of
the complex were recorded in CH2Cl2 solution, in a Hewlett Packard
diode array—8452A. The electron paramagnetic resonance (EPR)
spectrum was measured in solid state at −160 °C using a Varian
E-109 instrument, recorded at the X band frequency, within a rectangu-
lar cavity (E-248) ﬁtted with a temperature controller. Cyclic voltamm-
etry (CV) experiments of the complexes in solution were promoted in
an electrochemical analyzer BAS model 100B. These experiments
were carried out at room temperature, in CH2Cl2 containing 0.10 M
Bu4N+ClO4− (TBAP) (FlukaPurum) as support electrolyte, and using
an one-compartment cell, with both working and auxiliary electrodes,
which were stationary Pt foils, while the reference electrode was
Ag/AgCl, 0.10 M TBAP in CH2Cl2. Under these conditions, the ferro-
cene is oxidized at 0.43 V (Fc+/Fc).
All NMR experiments were run on a BRUKER, DRX400 MHz equip-
ment, in a BBO 5 mm probe, at 298 K, and TMS (tetramethylsilane) for
internal reference. For 1H and 13C NMR, DMSO-d6 was used as solvent,
while CH2Cl2 was used as solvent for (31P{1H}) NMR. The splitting of
proton, carbon and phosphorus resonances was reported as s = singlet
and m= multiplet.
2.3. X-ray crystallography
Blue single crystals of complexes (1) and (5) were grown by slow
evaporation of a dichloromethane/n-hexane solution. X-ray diffraction
experiments were carried out using a suitable crystal mounted on
glass ﬁber, and positioned on the goniometer head. Intensity data
were measured with the crystal at room temperature on an Enraf–
Nonius Kappa-CCD diffractometer with graphite monochromated
MoKα radiation (λ= 0.71073 Å). The cell reﬁnements were performed
using the software Collect [21] and Scalepack [22], and the ﬁnal cell pa-
rameters were obtained on all reﬂections. Data reduction was carried
out using the software Denzo-SMN and Scalepack [22]. The structures
were solved by the Direct method using SHELXS-97 [15] and reﬁned
using the software SHELXL-97 [23]. A Gaussian method implemented
was used for the absorption corrections [24]. Non-hydrogen atoms of
the complexes were unambiguously located, and a full-matrix, least-
square reﬁnement of these atoms with anisotropic thermal parameters
was carried out. The aromatic C\H hydrogen atoms were positioned
stereochemically and were reﬁned with ﬁxed individual displacement
parameters [Uiso(H)= 1.2 Ueq(Csp2)] using a ridingmodel with an aro-
matic, C\H bond length ﬁxed at 0.93 Å. Methylene groups of the dppb
ligand in the complex (5), andmethine groupof the lapacholwere set as
isotropic with a thermal parameter 20% greater than the equivalent
isotropic displacement parameter of the atom to which each one
was bonded, whereas methyl groups were set with Uiso(H) values of
1.5Ueq(Cmethyl). Tables were generated byWinGX [25] and the structure
representations by ORTEP-3 [18] and MERCURY [21]. The main crystal
data collections and structure reﬁnement parameters for (1) and (5)
are summarized in Table 1.
2.4. Synthesis
All the solvents used in this work were of reagent quality and used
without further puriﬁcation. Lapachol was obtained according to the
procedure described in [24]. The precursors cis-[RuCl2(PPh3)2(X-bipy)]
(X = H, methyl (Me) and methoxy (MeO)) and cis-[RuCl2(PPh3)2
(phen)] were prepared according to literature [26,27]. Typically
[100.0 mg; 0.1 mmol] of the [RuCl2(PPh3)3] was dissolved in degassed
20 mL of dichloromethane (Merck) and N-heterocyclic (X-bipy or
Fig. 1. Lapachol structure.
Table 1
Crystal data and structure reﬁnement for complex [Ru(Lap)(PPh3)2(bipy)]PF6 (1) and
[RuCl2(Lap)(dppb)] (5).
[Ru(Lap)(PPh3)2(bipy)]PF6 [RuCl2(Lap)(dppb)]
Empirical formula [RuC61H51N2O3P2]PF6 [RuC43H41Cl2O3P2]
Formula weight 1168.02 839.67
Crystal system Monoclinic Monoclinic
Space group P21/c P21/c
Unit cell dimensions
a (Å) 15.950(5) 9.1790(1)
b (Å) 16.744(5) 29.6950(5)
c (Å) 20.316(5) 14.7120(3)
β (o) 93.151(5) 104.564(1)
Volume (Å3) 5418(3) 3881.20(11)
Z 4 4
Density calculated
(Mg/m3)
1.432 1.437
μ (mm−1) 0.447 0.663
F(000) 2392 1724
Crystal size (mm3) 0.26 × 0.28 × 0.53 0.11 × 0.19 × 0.29
θ range (°) 2.96 to 26.76° 2.94 to 26.75°
Index ranges −20 ≤ h ≤ 20
−19 ≤ k ≤ 21
−25 ≤ l ≤ 23
−11 ≤ h ≤ 8
−37 ≤ k ≤ 37
−18 ≤ l ≤ 18
Reﬂections collected 36,197 27,401
Independent reﬂections 11,479 [R(int) = 0.0423] 8251 [R(int) = 0.0617]
Completeness to θ 99.4% 99.7%
Max. and min.
transmission
0.942 and 0.795 0.947 and 0.867
Data/restraints/
parameters
11,479/0/687 8251/0/462
Goodness-of-ﬁt on F2 1.209 1.129
Final R indices
[I N 2sigma(I)]
R1 = 0.0566,
wR2 = 0.1321
R1 = 0.0376,
wR2 = 0.0724
R indices (all data) R1 = 0.0669,
wR2 = 0.1386
R1 = 0.0692,
wR2 = 0.0776
Δρmax.andΔρmin.
(e.Å−3)
0.553 and−0.641 0.557 and−0.541
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phen) [22.0 mg; 0.11 mmol] ligand was added. The reaction mixture
was stirred for 30 min at room temperature and the volume of the
resulting blue solution was reduced, under vacuum, to ca. 2 mL and
diethyl ether (Merck) was then added to precipitate a red solid, which
was ﬁltered off, washed several times with diethyl ether, and dried
under vacuum. Yield: ~78 mg (80–90%).
Microanalyses suggested the formation of the complexes with
general formula [Ru(Lap)(PPh3)2(bipy)]PF6 (1), [Ru(Lap)(PPh3)2(Me-
bipy)]PF6 (2), [Ru(Lap)(PPh3)2(MeO-bipy)]PF6 (3), [Ru(Lap)(PPh3)2
(phen)]PF6 (4) and [RuCl2(Lap)(dppb)] (5). The molar conductivity
data reveal that the complex 5 (3.46 μS cm−1) is non-electrolyte and
complexes 1–4 (129.1, 146.8, 166.2 and 125.0 μS cm−1 respectively)
are 1:1 electrolytes (CH2Cl2), in accordance with the proposed
formulations.
2.4.1. [Ru(Lap)(PPh3)2(X-bipy)] and [Ru(Lap)(PPh3)2(phen)]
The ruthenium(II) complexes with N-N = bipy(1), Me-bipy(2),
MeO-bipy(3) and phen(4) were prepared by reacting an excess of
lapachol ligand (0.137 mmol; 33.0 mg), previously dissolved in
degassedmixture of CH2Cl2:MeOH(50:50) solvent, and the sameequiv-
alent of triethylamine Et3N, and the cis-[RuCl2(PPh3)2(N-N)] precursors
(0.114 mmol; ≅100.0 mg). The reaction mixture was reﬂuxed and
stirred for about 72 h, under Ar atmosphere. The ﬁnal blue solutions
were concentrated to ca. 2 mL and 10 mL of water was added in order
to obtain dark blue precipitates. The solids were ﬁltered off, well rinsed
with water and diethyl ether and dried in vacuum.
2.4.1.1. [Ru(Lap)(PPh3)2(bipy)]PF6 (1). Yield: 121 mg (88%). Anal. calcd
for C61H51F6N2O3P3Ru: exptl (calc) C, 62.30 (62.72); H, 4.20 (4.40); N,
2.18 (2.40). 31P{1H} NMR: δ(ppm) 29.3 (s); 1H NMR (400.21 MHz,
DMSO-d6, 298 K): δ(ppm) 9.80–7.00 (overlapped signals, 30H aromatic
hydrogen for PPh3 and 14H aromatic hydrogen for bipy and Lap) 4.88
(m, 1H, CH of Lap); 3.22 (m, 2H, CH2 of Lap); 1.83 (s, 3H, CH3 of Lap);
1.56 (s, 3H, CH3 of Lap). 13C NMR (400.21 MHz, DMSO-d6, 298 K):
δ(ppm) 198.1 (C1_O of Lap), 180.6 (C4_O of Lap), 167.2 (C2\O of
Lap). UV–vis (CH2Cl2, 10−5 M): λ/nm (ε/M−1 L cm−1) 370 (shoulder),
573 (6.30 × 103).
2.4.1.2. [Ru(Lap)(PPh3)2(Me-bipy)]PF6.CH3OH (2). Yield: 115 mg (84%).
Anal. calc. for C64H59F6N2O4P3Ru: exp (calc) C, 62.70 (62.59); H, 4.61
(4.84); N, 2.32 (2.28). 31P{1H} NMR: δ(ppm) 29.1 (s); 1H NMR
(400.21 MHz, DMSO-d6, 298 K): δ(ppm)2.30 (s, 3H, CH3); 2.42 (s, 3H,
CH3′) (aliphatic hydrogen for Me-bipy); 8.09–7.00 (overlapped signals,
30H aromatic hydrogen for PPh3 and 8H aromatic hydrogen of Me-
bipy); 4.87 (m, 1H, CH of Lap); 3.19 (m, 2H, CH2 of Lap); 1.81 (s, 3H,
CH3 of Lap); 1.55 (s, CH3 of Lap).13C NMR (400.21 MHz, DMSO-d6,
298 K): δ(ppm) 198.7 (C1_O of Lap), 182.3 (C4_O of Lap), 168.0
(C2\O of Lap). UV–vis (CH2Cl2, 10−5 M): λ/nm (ε/M−1 cm−1) 297
(shoulder), 572 (6.40 × 103).
2.4.1.3. [Ru(Lap)(PPh3)2(MeO-bipy)]PF6 (3). Yield: 110 mg (84%). Anal.
calcd for C63H55F6N2O5P3Ru: exp.(calc) C, 61.97 (61.61); H, 4.39
(4.51); N, 2.43 (2.28). 31P{1H} NMR: δ(ppm) 29.8 (s). 1H NMR
(400.21 MHz, DMSO-d6, 298 K):δ(ppm) 3.91 (s, 3H, CH3); 3.84 (s, 3H,
CH3′) (aliphatic hydrogen ofMeO-bipy); 9.45–7.00 (overlapped signals,
30H aromatic hydrogen for PPh3 and 12H aromatic hydrogen for MeO-
bipy and Lap); 4.85 (m, 1H, CH of Lap); 3.16 (m, 2H, CH2 of Lap); 1.80
(s, 3H, CH3 of Lap); 1.54 (s, CH3 of Lap).13C NMR (400.21 MHz, DMSO-
d6, 298 K): δ(ppm) 198.2 (C1_O of Lap), 180.4 (C4_O of Lap), 167.6
(C2\O of Lap). UV–vis (CH2Cl2, 10−5 M): λ/nm (ε/M−1 cm−1) 297
(shoulder), 586 (6.11 × 103).
2.4.1.4. [Ru(Lap)(PPh3)2(phen)]PF6(4). Yield: 128 mg (94%). Anal. calcd
for C63H51F6N2O3P3Ru: exp.(calc) C, 63.97 (63.48); H, 3.99 (4.31); N,
2.39 (2.35). 31P{1H} NMR: δ(ppm) 32.6 (s). 1H NMR (400.21 MHz,
DMSO-d6, 298 K):δ(ppm)10.00–7.00 (overlapped signals, 30H aromatic
hydrogen of PPh3 and 18H aromatic hydrogen for phen and Lap); 4.91
(m, 1H, CH of Lap); 3.26 (m, 2H, CH2 of Lap); 1.83 (s, 3H, CH3 of Lap);
1.55 (s, CH3 of Lap).13CNMR (400.21 MHz, DMSO-d6, 298 K): δ(ppm)
198.4 (C1_O of Lap), 180.6 (C4_O of Lap), 167.4 (C2\O of Lap). UV–
vis (CH2Cl2, 10−5 M): λ/nm (ε/M−1 L cm−1) 290 (shoulder), 300
(2.66 × 104), 408 (5.25 × 103).
2.4.1.5. [RuCl2(Lap)(dppb)], (5). The ruthenium (III) complex [RuCl2
(Lap)(dppb)] (5) was prepared dissolving (0.137 mmol; 33.0 mg) of
lapachol ligand in a mixture of CH2Cl2:MeOH (50:50) solvent and the
same equivalent of triethylamine (Et3N) and then added the mer-
[RuCl3(dppb)(H2O)] [28] precursor (0.137 mmol; 33.0 mg). The reac-
tion mixture was reﬂuxed and stirred for 24 h, under Ar atmosphere.
The ﬁnal purple solution was concentrated to ca. 2 mL, and 10 mL of
diethyl ether was added in order to obtain dark purple precipitate.
The solid was ﬁltered off, well rinsed with diethyl ether and dried in
vacuo. Yield: 189 mg (98%). Anal. calc. for C43H41Cl2O3P2Ru: exp.
(calc) C, 61.40 (61.50); H, 4.80 (4.92). UV–vis (CH2Cl2, 10−5 M): λ/nm
(ε/M−1 L cm−1) 315 (shoulder), 330 (shoulder), 356 (2.77 × 103) and
558 (5.6 × 103).
2.5. Biological experiments
2.5.1. Cells and cultures
Antiparasitic activity was performed with Leishmania amazonensis
(MHOM/BR88/BA-125) and W2 strain Plasmodium falciparum, while
hemolysis assayswere done usingO+ human erythrocytes and cytotox-
icity assays were done in J774 macrophages. The L. amazonensis
promastigotes were maintained in Schneider's insect medium (Sigma-
Aldrich, St. Louis, USA) supplemented with 10% fetal bovine serum
(Gibco Laboratories, Gaithersburg, USA) and 50 μg/mL of gentamicin
(Hipolabor, Belo Horizonte, Brazil). J774 macrophages were cultivated
in RPMI-1640 medium (Sigma-Aldrich, St. Louis, USA) supplemented
with 10% fetal bovine serum and 50 μg/mL of gentamicin. W2 strain
P. falciparumwas maintained in continuous culture of human erythro-
cytes (blood group O+) using RPMI-1640 medium supplemented with
10% human plasma without hypoxanthine.
2.5.2. Cytotoxicity assays
J774 macrophages (5 × 104 cells/mL) were distributed in 96-well
plate (100 μL/well) and incubated for 24 h at 37 °C in 5% CO2. Each
drug was solubilized in DMSO as a stock solution and diluted in culture
media in the tested concentrations ranging from 0.1 to 10 μg/mL
(100 μL/well). The ﬁnal concentration of DMSO was 0.1%. Each concen-
trationwas tested in triplicate. After incubation for 72 h, 20 μL of Alamar
blue (Invitrogen, CA, USA) was added to eachwell and incubated for 24
h in the dark. Gentian violet was used as control. The absorbance was
evaluated at 570 and 600 nm according to manufacturer's instructions.
The LC50 values were calculated using a non-linear regression curve ﬁt
in the Prism version 5.03 (GraphPad Software).
For the hemolysis assay, human erythrocytes type O+ were washed
three times in phosphate buffered saline and 100 μL of this suspension
(1% hematocrit) was distributed into a 96-well plate. Then, 100 μL of
each drug, previously dissolved in phosphate buffered saline, was
added in triplicate to the plate and incubated for 1 h. Saponin (Sigma-
Aldrich, St. Louis, USA) was used as reference drug at 1% v/v. After incu-
bation the cells were centrifuged (1500 rpm for 10 min) and 100 μL of
each supernatant was transferred to another microtiter plate. Released
haemoglobin was monitored by measuring the absorbance at 540 nm
in a spectrophotometer. The percentage of hemolysis was determined
in comparison to untreated cells.
2.5.3. Antileishmanial activity against promastigotes
L. amazonensis promastigotes (2 × 106 cells/mL) in stationary
growth phase were distributed in a 96-well plate (100 μL/well) at
24 °C. Each drug was solubilized in DMSO as described above,
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diluted in the culture medium and added in serial dilution from 0.1
to 10 μg/mL (100 μL/well). The ﬁnal DMSO concentration was 0.1%.
Amphotericin B (Gibco Laboratories, Gaithersburg, USA) was used as
reference drug. After 72 h incubation at 24 °C, the number of viable par-
asites was counted in a Neubauer chamber. The IC50 values were calcu-
lated in Prism version 5.03 (GraphPad Software) using non-linear
regression.
2.5.4. In vitro leishmania infection
J774 macrophages (2 × 105cells/mL) were plated in 96-well plate
(100 μL/well) and incubated overnight at 37 °C in 5% CO2.
L. amazonensis promastigotes in the stationary growth phase were
added to the cell culture (100 μL/well) at a parasite/macrophage ratio
of 10:1 and incubated for 24 h. Plates were washed to remove non-
phagocytosed parasites. Each drug, solubilized as described above, was
added and incubated for 72 h. Amphotericin B was used as reference
drug. Infectedmacrophages were lysed by addition of 0.01% sodiumdo-
decyl sulfate (Sigma-Aldrich, St. Louis, USA) in PBS (phosphate-buffered
saline) at 37 °C for 30 min.
Amastigotes from lysed macrophages were incubated at 24 °C for
48 h, which then differentiated in promastigotes. The number of viable
promastigotes was determined by adding Alamar Blue (20 μL/well) and
incubated for 24 h. The absorbance was evaluated at 570 and 600 nm
according to the manufacturer's instructions. The IC50 values were cal-
culated in Prism version 5.03 (GraphPad Software) using non-linear
regression.
2.5.5. Antimalarial activity
The antimalarial effects of the compounds were measured with the
[3H]-hypoxanthine (PerkinElmer, Boston, USA) incorporation assay.
W2 P. falciparum grown at 1–2% parasitemia and 2.5% hematocrit were
aliquoted in a 96-well plate. Drugs were solubilized as described above
in a concentration range of 0.1 to 10 μg/mL; each concentrationwas per-
formed in triplicates. Meﬂoquine (Farmanguinhos, Rio de Janeiro, RJ,
Brazil) was used as reference drug. After 24 h of incubationwith the test-
ed compounds, 25 μL of medium containing [3H]hypoxanthine (0.5 μCi/
well) was added per well, followed by another 24 h of incubation. The
parasites were harvested using a cell harvester to evaluate the [3H]-hy-
poxanthine incorporation in a β-radiation counter (Multilabel Reader;
Hidex, Turku, Finland). Inhibition of parasite growth was evaluated by
comparing the [3H]-hypoxanthine uptake in untreated versus treated
cells. IC50 values were calculated in a Graph Pad Prism version 5.03
(Graph Pad Software, San Diego, CA) using non-linear regression.
3. Results and discussion
In this work the lapachol acted as bidentate ligand and monoanionic
species, coordinating with the ruthenium atoms through its ortho oxy-
gens (O1, O2—Fig. 1). The structures of the complexes [Ru(Lap)(PPh3)2
(bipy)]PF6 (1) and [RuCl2(Lap)(dppb)] (5) were conﬁrmed based on
X-ray diffraction data (see Fig. 2). These compounds crystallize in the
Fig. 2. X-ray structures for (a) [Ru(Lap)(PPh3)2(bipy)]PF6 (1) and (b) [RuCl2(Lap)(dppb)] (5), showing atoms labeling and 50% of probability ellipsoids.
Table 2
Selected bond length (Ả) and angles (°) for complexes (1) and (5).
Fragment Complex (1) Complex (5)
Ru(1)–O(1) 2.0710(19) 2.1707(15)
Ru(1)–O(2) 2.133(2) 2.0580(15)
Ru(1)–P(2) 2.3952(11) 2.3728(6)
Ru(1)–P(1) 2.4104(10) 2.2910(6)
Ru(1)–N(2) 2.038(2) –
Ru(1)–N1(1) 2.050(2) –
Ru(1)–Cl(1) – 2.3308(7)
Ru(1)–Cl(2) – 2.3343(7)
O(1)–C(1) 1.250(3) 1.235(3)
O(2)–C(2) 1.308(3) 1.309(3)
O(3)–C(4) 1.236(4) 1.230(3)
O(2)–Ru(1)–O(1) 76.22(7) 77.85(6)
O(1)–Ru(1)–P(1) 174.56(5) 91.69(6)
O(2)–Ru(1)–P(2) 90.02(6) 171.11(5)
O(1)–Ru(1)–P(2) 89.95(6) 93.39(5)
P(1)–Ru(1)–P(2) 178.25(3) 92.01(2)
Cl(1)–Ru(1)–Cl(2) – 168.99(3)
Table 3
Cyclic voltammetry data for complexes (1)–(4) (TBAP 0.1 M; CH2Cl2; Ag/AgCl; work
electrode Pt; 100 mVs−1).
Complex Epa (V) E1/2 (V) pKa (N–N)
[Ru(Lap)(PPh3)2(bipy)]PF6 (1) 1.03 0.99 4.86
[Ru(Lap)(PPh3)2(Me-bipy)]PF6 (2) 0.96 0.87 4.92
[Ru(Lap)(PPh3)2(MeO-bipy)]PF6 (3) 0.77 0.71 5.74
[Ru(Lap)(PPh3)2(phen)]PF6 (4) 1.08 1.00 4.44
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monoclinic system,with the space group P21/c. It is observed that the O1
and O2 atoms are involved in the coordination, where O2, is negatively
charged and O1, is neutral. A distorted octahedral geometry is observed
for both crystal structures, as observed by the bond angles (Table 2).
Some distance and selected angles in the X-ray structure of complex
(1) and (5) are shown in Table 2, which are, in general, in accordance
with values expected for similar phosphine complexes of Ru(II) and
Ru(III) for Ru–N, Ru–P and Ru–Cl [28–30]. But, it is interesting to point
out that the distances of Ru(II)–O for complex (1) are also in accordance
with the expected values,where the distance Ru–O2 [2.133(2)Ả] is lon-
ger than the distance Ru–O1 [2.0710(19) Ả], since the O2 has charge
minus one and its radius is bigger than the one for the neutral species.
Therefore, the same was not observed for complex (5), where the dis-
tance Ru–O1 [2.1707(15) Ả] is longer than the distance Ru–O2
[2.0580(15) Ả]. Probably in this case the strong trans effect of phospho-
rus atoms is more effective when it is trans to neutral atoms, and not
when it is trans to negatively charged atoms. As it can be seen in
Table 2 the distance of Ru(III)–O1 is 0.1 Ả longer than Ru(II)–O1, show-
ing the strong trans effect phosphorus atoms. On other hand the dis-
tance Ru(III)–O1, is shorter than Ru(II)–O1, as expected, considering
the size of the radius of Ru(III) and Ru(II).
In the 31P{1H} NMR spectra of the complexes (1–4) just one singlet
at about 30 ppm is observed in all cases, indicating the magnetic equiv-
alence of the two trans phosphorus atoms, as expected. Also, each 31P
{1H} NMR spectra exhibit a heptet signal at−144 ppm, corresponding
to the phosphorus atoms of the PF6− counter ion. The EPR spectra in
solid state, for complex (5), conﬁrms the presence of Ru (III) paramag-
netic species, showing g1 = 2.578, g2 2.128 and g3 = 1.822 typical of
ruthenium (III) complexes [29].
Cyclic voltammograms of Ru(II) complexes (1–4) show a quasi-
reversible process between 0.71 and 1.0 V, which correspond to the
redox pair Ru(III)/Ru(II), as can be seen from the Table 3, and Fig. 3 for
the case of complex (4). In the negative region a quasi-reversible one-
electron reduction process was observed in all cases, which most prob-
ably correspond to the ligand reduction to the semiquinone form [31].
As can be seen in Table 3 the redox potential of 1–4 decreases when
the diimine basicity is increased. Analyzing the complex [RuCl2
(Lap)(dppb)] (5), in the same experimental conditions, it is observed
a Ru(III)/Ru(II) reversible process with E1/2 of 0.18 V.
The IR spectra of complexes (1–5) conﬁrm the presence of
the lapachol ligand coordinated to the metal. The band located at
3351 cm−1 in the free lapachol [31,32] assigned to OH, disappears upon
coordination, as expected. The characteristic ν(C_O) stretching bands,
found at ν(C1_O) 1664 and ν(C4_O) 1641 cm−1 in free lapachol
[11] shifted to lower frequencies in complexes, 1561–1591 cm−1 and
1581–1533 cm−1, respectively. This behavior was also observed for
other complexes like Ru(II), Co(II), Ni(II) and Cu(II) containing the
lapachol as ligand [5,11,12]. The characteristic ν(C2\O) stretching band
found in 1028 cm−1 in the free lapachol shifted to higher frequencies in
complexes (1065–1079 cm−1). Finally, newbands ofmedium intensities,
located below 500 cm−1 are present in the spectra of complexes, which
may be related to metal–ligand vibrations.
The antiparasitic and toxicity of host cell were evaluated. For com-
parison, the metal-free lapachol was included in the pharmacological
evaluation. Firstly, compounds were evaluated on their ability to inhibit
the L. amazonensis promastigote proliferation, as well as against intra-
cellular amastigotes, according to standardmethodology [33]. Secondly,
the antimalarial activity of the complexes was determined against the
erythrocytic stage of W2 strain P. falciparum. Host cell cytotoxicity in
J774 macrophages as well as the hemolysis in uninfected erythrocytes
was determined [34,35]. The results were expressed in terms of IC50
and LC50 values. Amphotericin B and meﬂoquine were respectively
Fig. 3. Cyclic voltammogram of [Ru(Lap)(PPh3)2(phen)]PF6 (4) (TBAP 0.1 M; CH2Cl2; Ag/AgCl; work electrode Pt; 100 mV.s−1).
Table 4
Antiparasitic activity and cytotoxicity for the ruthenium complexes.
Compounds L. amazonensis, IC50 ± SEM(μM) P. falciparum(c)
IC50 ± SEM(μM)
Cytotoxicity(d)
LC50 ± SEM(μM)
SI(e)
Promastigotes(a) In vitro infection(b)
Lapachol 12.4 ± 0.69 N10 11.3 ± 4.1 N10 N.D.
(1) N10 0.07 ± 0.002 43.5 ± 0.71 0.33 ± 0.08 4.7
(2) 0.18 ± 0.04 0.17 ± 0.01 0.35 ± 0.26 1.0 ± 0.46 5.9
(3) 0.42 ± 0.03 N10 0.53 ± 0.28 6.7 ± 1.3 N.D.
(4) 1.6 ± 0.44 N.D. 0.19 ± 0.17 1.9 ± 1.3 N.D.
(5) 0.14 ± 0.04 0.57 0.21 ± 0.10 N10 17.5
Meﬂoquine – – 0.04 ± 0.01 – N.D.
Amphotericin B 0.13 ± 0.01 0.23 ± 0.09 – N10 N.D.
Gentian Violet – N.D. N.D. 0.60 ± 0.07 –
(a)Values determined 72 h after incubation with drugs. (b)Values determined for infected macrophages 72 h after incubation with drugs (c)Determined against W2 strain P. falciparum
(erythrocytic stage) 24 h after incubation with drugs. (d)Cytotoxicity was determined in J774 macrophages after 72 h incubation with drugs. (e)SI value is given from the ratio LC50 in
J774/IC50 (L. amazonensis, in vitro infection). IC50 and LC50 values were determined from two independent experiments, concentration in triplicates. SEM = standard error of the
mean; N.D. = not determined. SI = selectivity index.
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used as reference drugs for Leishmania and Plasmodium tests respective-
ly, while gentian violet was used as control in host cell cytotoxicity.
Amphotericin B, which was used as a reference drug, exhibited an
IC50 = 0.13 ± 0.01 μM, while lapachol was in practice, inactive against
L. amazonensis promastigotes. Complex (1) was inactive to inhibit
promastigotes, while complexes (2–5) were able to inhibit their prolif-
eration. Speciﬁcally, complexes (2) and (5) exhibited activity against
promastigotes similar to the observed for amphotericin B. Regarding
the inhibitory activity in L. amazonensis-infected macrophages,
amphotericin B displayed an IC50 = 0.23 ± 0.09 μM, while lapachol
was inactive. In this assay, complexes (3) and (4) were also inactive.
In contrast, complexes (1), (2) and (5) were able to reduce the Leish-
mania infection in macrophages, with similar potency to the observed
for amphotericin B.
The cytotoxicity towards host cells was also determined for all ﬁve
complexes, including lapachol. Gentian violet had a LC50 = 0.60 ±
0.07, while lapachol was non-toxic, having a LC50 N 10 μM for J774mac-
rophages. In comparison to lapachol, complexes (1–4) were more cyto-
toxic, while complex (5) was not cytotoxic. The selectivity index was
calculated and shown in Table 4. Considering the antileishmania activi-
ty, complex (5) exhibited high selectivity index, while complexes (1–2)
showed indexes lower than complex (5).
Next, the antimalarial activity for these complexes was evaluated.
Lapachol displayed aweak activity to inhibit P. falciparum in comparison
tomeﬂoquine. It was observed that complex (1) showed a poor activity,
while the complexes (2–5) were several times more potent than free
lapachol. The most potent complexes against P. falciparum were (4)
and (5). These complexes were ﬁfty times more potent than free
lapachol and only ﬁve times less potent than meﬂoquine. In addition,
the effects of complexes (1–5), as well as of free lapachol, in causing he-
molysiswere evaluated and thepercentage of hemolysiswas calculated.
Saponin, was used as the reference drug to cause hemolysis to the
erythrocytes (Fig. 4). Lapachol did not cause hemolysis. The complexes
(1–5) failed to cause not even 50% of hemolysis at 200 μM. This suggests
that the reported anti-P. falciparum activity was not caused by the red
blood cells lyses.
4. Conclusions
In summary, ﬁve new ruthenium (II) and (III) complexes containing
lapachol as ligandwere synthesized and characterized by a combination
of NMR, EPR, FTIR, and X ray diffraction techniques. The evaluation of
antiparasitic activities of the complexes against L. amazonensis and
P. falciparum demonstrated that the lapachol–ruthenium complexes are
more potent than the free lapachol. The [RuCl2(Lap)(dppb)] complex is
the most potent and selective antiparasitic compound among the ﬁve
new ruthenium complexes studied in this work, exhibiting an
activity comparable to the one of reference drugs. Speciﬁcally,
lapachol–ruthenium complexes displayed potent and selective
antileishmanial activity.
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